Astra USA Naropin safety data includes 218 C-section, 220 labor and delivery patients.
Executive Summary
ASTRA USA NAROPIN DATA INCLUDE EIGHT C-SECTION, NINE L&D SAFETY STUDIES, which were presented at a Dec. 12 Anesthetic & Life Support Drugs Advisory Committee review of the neuromuscular blocker ropivacaine. Astra USA presented data from eight studies performed in 218 Cesarean section patients receiving doses up to 150 mg of ropivicaine .5% concentration and nine studies of 220 labor and delivery patients receiving .25% ropivacaine. "The Pink Sheet" (Dec. 18, 1995, p. 7) incorrectly reported that Naropin safety data for use in pregnant women were derived exclusively from animal studies.You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: